Azithromycin
Evidence level: small uncontrolled human study (abstract only); guideline abstract only; registry entries
A macrolide antibiotic that appears in the BOS literature, in a small uncontrolled study, in a guideline abstract and in registered trials.
As of . Primary source: Verleden et al. 2006 (DOI).
Summary
The 2006 study by Verleden and colleagues, recorded on this site, gave azithromycin to 14 lung transplant patients with BOS who were also receiving immunosuppression. According to its abstract, mean FEV1 rose from 2.36 to 2.67 litres and the percentage of lavage neutrophils fell from 35.1 to 5.7 percent over three months; the study was small and uncontrolled. The abstract of the 2014 ISHLT/ATS/ERS guideline lists azithromycin among the topics on which the committee made recommendations, and states that available therapies have not been proven to give significant benefit in preventing or treating BOS; the individual recommendations were not read for this record. The registry entry for the ROCKaspire trial lists azithromycin as background therapy in both arms, and a completed KU Leuven registry entry reports posted results (see the trial record). This record describes the literature and gives no dosing and no advice.
Details
- interventionType
- drug (macrolide antibiotic)
Sources and links
Related
Links from this record
- described in: Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome
- named in: An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome
- studied in: Bronchiolitis obliterans syndrome (BOS)
Linked from (derived)
- tests: Azithromycin in Bronchiolitis Obliterans Syndrome
- background therapy in both arms: A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction
- assesses: European society for organ transplantation clinical practice guideline on prevention and treatment of chronic lung allograft dysfunction
- reports use of: Chronic lung allograft dysfunction after lung transplantation: prevention, diagnosis and treatment in 44 European centres
- discusses: Global approaches to chronic lung allograft dysfunction: Toward evidence-based harmonization
- affects: No therapy of proven benefit for established CLAD
- affects: CLAD care and measurement vary between centres
Known gaps in this record
- full text of the guideline and its recommendation strength: not read
- dosing: deliberately not recorded
- efficacy in randomised trials: not assessed here; only registry-posted numbers on the trial record
Information resource only. Not medical advice. Not a substitute for the care of the patient's transplant team.